TNBC is a subtype of breast cancer characterized by the absence of estrogen, progesterone, and HER2 receptors, which limits the effectiveness of many targeted therapies. The aggressive nature of TNBC is partly due to its early and rapid metastatic potential, complicating treatment and often leading to poorer prognoses. Until now, the role of the tumor microenvironment, particularly the impact of fat tissue in cancer progression, has remained elusive. The new study unveils how adipose tissue, far from being passive, actively facilitates tumor spread through specialized extracellular vesicles known as adipomes.

Adipomes are tiny, extracellular vesicles secreted by fat cells that serve as molecular messengers within the tumor microenvironment. What makes this discovery particularly compelling is the elucidation of how these adipomes initiate and promote the metastatic cascade in TNBC. By harnessing advanced purification techniques capable of isolating pure adipomes from intact tissues and bodily fluids, the team could detail the molecular crosstalk between adipose tissue and cancer cells. This pioneering methodology overcomes a significant technical hurdle that has historically hampered research progress, and it is currently the subject of a pending U.S. patent application filed by Hackensack Meridian Health.

The study shows that adipomes carry a distinct ‘lipid code’ that reprograms triple-negative breast cancer cells at the molecular level. This lipid signaling activates stress-response pathways, enhances protein synthesis, and upregulates mitochondrial signaling and translational machinery. These molecular alterations culminate in the formation of invadopodia—dynamic, actin-rich protrusions that penetrate the extracellular matrix. Invadopodia play a crucial role in cancer cell invasion, facilitating tissue degradation and enabling cancer cells to breach local tissue barriers and disseminate to distant organs.

Traditionally, tumor-adjacent adipocytes have been viewed as static reservoirs of energy that merely supply fatty acids to tumors. However, the current study challenges this dogma by demonstrating that adipocytes, through the secretion of adipomes, are active participants and orchestrators in the mammary tumor microenvironment. This dynamic interaction represents a previously unrecognized tumor-adipocyte signaling axis, crucial for the initiation and progression of metastasis in TNBC. Understanding this axis expands our knowledge of cancer biology and may pinpoint novel biomarkers or therapeutic targets.

The metastatic cascade in breast cancer has long been understood to initiate with cancer cells invading the stromal tissue, a process heavily facilitated by invadopodia. While the structural and functional properties of invadopodia are well characterized, the triggering mechanisms that lead to their formation have remained obscure. The current research specifically targets the pre-invadopodia phase, revealing that adipomes act as upstream influencers that ‘prime’ cancer cells for metastasis by setting off the molecular machinery necessary for invadopodia development.

Utilizing human clinical samples obtained from the Hackensack Meridian Health Network Biorepository and a variety of preclinical models, the researchers meticulously detailed every step of this metastatic progression. Their approach included isolating and profiling adipomes, assessing their lipid content, and analyzing the downstream signaling cascades activated in the cancer cells. The results illuminate how adipose tissue-derived vesicles extend beyond local interactions to influence distant metastatic niches, effectively hijacking normal cellular communication pathways to benefit tumor invasion and dissemination.

This profound insight into adipome-mediated signaling provides a plausible explanation for the notoriously high metastatic propensity of TNBC. By manipulating cellular stress responses and protein production, adipomes equip cancer cells with enhanced invasive capabilities, thus facilitating rapid disease progression. The identification of this signaling axis offers hope that new therapeutic strategies may emerge, aimed at disrupting adipome formation, release, or cancer cell reprogramming, potentially halting or reversing the progression of TNBC.

The implications of these findings reach beyond breast cancer alone. Dr. Nagajyothi’s laboratory has an extensive research portfolio that explores the role of adipose tissue in various diseases, including infectious diseases such as Chagas cardiomyopathy and pulmonary tuberculosis, as well as metabolic disorders like type 2 diabetes and lean diabetes. The current study underscores the multifaceted influence of adipose tissue in systemic disease processes, demonstrating its critical role in both infectious and non-infectious pathologies.

Looking forward, the research team envisions the development of novel diagnostic tools and interventions targeting the tumor-adipocyte communication mediated by adipomes. The ability to detect and potentially neutralize these vesicles could enable early intervention in metastatic TNBC, significantly improving patient outcomes. Moreover, the group’s proprietary isolation technique for adipomes, protected under a pending patent, stands poised to accelerate research and therapeutic development in this emerging field.

In summation, this pioneering work sets a new paradigm in cancer biology by firmly establishing adipomes as key regulators of metastatic behavior in triple-negative breast cancer. It powerfully illustrates how the tumor microenvironment, particularly adipose tissue, contributes actively to cancer progression. As researchers worldwide continue to unravel the complexities of tumor-host interactions, these insights pave the way for breakthrough therapeutic strategies aimed at one of the most challenging cancer subtypes known today.

Subject of Research: Human tissue samples

Article Title: Cancer-associated adipomes promote invadopodia formation and enhance metastatic potential in triple-negative breast cancer

News Publication Date: 3-Jun-2026

Web References:
https://doi.org/10.1038/s41523-026-00985-2

References:
Nagajyothi, J., Thangavel, H., Glazer, R., et al. (2026). Cancer-associated adipomes promote invadopodia formation and enhance metastatic potential in triple-negative breast cancer. npj Breast Cancer. https://doi.org/10.1038/s41523-026-00985-2

Image Credits: Hackensack Meridian Health

Keywords: Breast cancer, triple-negative breast cancer, metastasis, adipose tissue, adipomes, tumor microenvironment, invadopodia, extracellular vesicles, lipid signaling, cancer metastasis

One of the most comprehensively studied pathways connecting obesity to cancer involves chronic inflammation. Excess adipose tissue, especially visceral fat, functions as an active endocrine organ, secreting proinflammatory cytokines such as tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6). This persistent low-grade inflammatory state disrupts normal immune surveillance and promotes a microenvironment conducive to DNA damage, angiogenesis, and ultimately oncogenesis. Importantly, the inflammatory signature varies depending on the fat depot and the metabolic state, influencing cancer initiation and progression differently across tissue types.

Hormonal dysregulation also constitutes a pivotal mechanism linking obesity with cancer risk. Adipose tissue facilitates peripheral conversion of androgens into estrogens via increased aromatase activity, thereby elevating circulating estrogen levels. Elevated estrogen, especially in postmenopausal women, has been implicated in the pathogenesis of hormone-sensitive cancers such as breast and endometrial cancer. Moreover, obesity-related insulin resistance leads to hyperinsulinemia and increased bioavailability of insulin-like growth factor 1 (IGF-1), both of which have mitogenic and anti-apoptotic properties that further propel tumorigenesis.

Adding another layer of complexity, adipokines—bioactive peptides secreted by adipocytes—play divergent roles in cancer biology. Leptin, generally elevated in obese individuals, has been shown to promote cancer cell proliferation, angiogenesis, and metastasis through activation of signaling pathways such as JAK/STAT and PI3K/Akt. Conversely, adiponectin, which exhibits anti-inflammatory and insulin-sensitizing effects, is typically reduced in obesity and is thought to exert protective effects against tumor development. The imbalance between leptin and adiponectin is thus believed to be a critical driver in obesity-associated carcinogenesis.

Recent research has also highlighted the emerging role of the gut microbiome in mediating obesity’s impact on cancer risk. Obesity-induced microbial dysbiosis alters the composition and function of intestinal flora, resulting in increased production of carcinogenic metabolites, impairment of the gut barrier, and systemic inflammation. These changes may facilitate oncogenic processes, particularly in colorectal and liver cancers. Given the modifiable nature of the microbiome, this represents a promising avenue for intervention.

Notably, the influence of obesity on cancer risk is not uniform across all cancer types or anatomical sites. As Professor Peng Luo notes, “Obesity may affect the risk of cancer at different sites to varying degrees through the same mechanism, which may be attributed to the heterogeneity of the role of the mechanism in the development of cancer at different sites.” For example, while inflammatory processes may be predominant in liver cancer pathogenesis, hormonal disturbances could play a more substantial role in breast or endometrial malignancies.

Given these intricate and site-specific biological interactions, personalized approaches to cancer prevention in obese individuals are gaining traction. Lifestyle modifications, including diet and physical activity, remain foundational strategies to reduce adiposity and its associated risks. However, emerging pharmacotherapies targeting weight loss, as well as bariatric surgical interventions, have demonstrated significant potential in not only achieving sustained weight reduction but also lowering cancer incidence among obese populations.

Furthermore, therapeutics aimed at mitigating obesity-related inflammation and hormonal imbalances are entering the clinical arena with encouraging results. Agents such as metformin, originally developed for type 2 diabetes, exhibit anti-inflammatory and antiproliferative effects that may translate into chemopreventive benefits. Likewise, selective estrogen modulators and aromatase inhibitors are being evaluated for their efficacy in disrupting obesity-driven hormonal pathways involved in tumorigenesis.

While considerable progress has been made in deciphering the obesity-cancer nexus, critical questions remain unanswered. The differential impact of obesity on cancer subtypes, the temporal dynamics of obesity-induced molecular changes preceding oncogenesis, and the identification of precise biomarkers to stratify cancer risk in obese individuals warrant further investigation. Additionally, integrating genetic and epigenetic factors with environmental and lifestyle data will be essential in developing robust predictive models.

Looking ahead, the study led by Professor Peng Luo underscores the necessity of a multidisciplinary approach that bridges molecular biology, clinical research, and public health. By unraveling the complex biological underpinnings of obesity-associated cancer risk, researchers aspire to inform the design of targeted, personalized prevention and treatment regimens. This paradigm shift has the potential to not only curb the global cancer burden but also improve the overall clinical outcomes for the increasingly prevalent population of obese patients.

In conclusion, obesity acts as a catalyst for cancer development through interconnected mechanisms involving inflammation, hormonal and metabolic dysregulation, adipokine imbalance, and microbial alterations. These pathways do not operate in isolation; rather, they collectively generate a pro-tumorigenic milieu that varies according to cancer site and individual biology. Addressing obesity with comprehensive, mechanism-informed strategies is paramount to advancing cancer prevention and therapy in the 21st century.

As research continues to unravel the nuances of how excess adiposity influences cancer biology, clinicians and public health experts must collaborate on translating these insights into effective interventions. Prevention strategies tailored to the unique risk profiles of obese individuals, coupled with innovative therapeutics targeting underlying biological derangements, herald a new era in oncology. Ultimately, this will help stem the tide of obesity-driven cancers and improve quality of life for millions worldwide.

Subject of Research: Not applicable
Article Title: Novel perspectives on the link between obesity and cancer risk: from mechanisms to clinical implications.
Web References: Not provided
References: Not provided
Image Credits: Not provided